[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005272
German
Original Title: Tremelimumab und Durvalumab (hepatozelluläres Karzinom)
Details
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Hepatocellular
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
Keywords
  • Durvalumab
  • Tremelimumab
  • Carcinoma – Hepatocellular
  • Benefit Assessment
  • NCT03298451
  • NCT03434379
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.